Related Experiment Video
Updated: Jun 4, 2026
A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease
Published on: January 29, 2021
Bispecific Antibody MDX-210 for Treatment of Advanced Ovarian and Breast Cancer
P A Kaufman1, P K Wallace, F H Valone
1Section of Hematology/Oncology, Dartmoth Hitchcock Medical Center, Lebanon, NH.
Abstract:
A large number of monoclonal antibodies (MAbs) to various tumor cell lines have been developed (1). However, MAbs have thus far had limited therapeutic impact in oncology, probably in part because many murine MAbs do not effectively recruit immune effector mechanisms, such as complement fixation and antibody-dependent cell-mediated cytotoxicity (ADCC) in humans. Additionally, although humanized MAbs are being developed, when used therapeutically their immunological effectiveness may be limited by high concentrations of nonspecific immunoglobulin (Ig) in patient serum. These nonspecific Ig will compete with conventional MAbs for binding to Type I Fc receptors (FcγRI) on immune effector cells, and may therefore limit conventional MAbs ability to recruit an immune response. Recently, however, clinical efficacy of a humanized MAb directed against HER-2/neu in patients with advanced breast cancer has been demonstrated (2-4). Preclinical data suggests that mechanistically this activity may be as a consequence of modulation of important biologic properties of the HER-2/neu receptor itself, as opposed to through an immunologic mechanism of tumor cell destruction.
Insights
Monoclonal antibodies (MAbs) show limited oncology impact due to poor human immune response. A humanized MAb targeting HER-2/neu demonstrates clinical efficacy in breast cancer, potentially via receptor modulation rather than immune cell destruction.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Monoclonal antibodies (MAbs) are developed for cancer therapy but often show limited efficacy.
- Murine MAbs may fail to activate human immune effector mechanisms like complement fixation and antibody-dependent cell-mediated cytotoxicity (ADCC).
- Nonspecific immunoglobulins in patients can interfere with MAb binding to Fc receptors, hindering immune responses.
Purpose of the Study:
- To evaluate the therapeutic potential of monoclonal antibodies in oncology.
- To investigate the mechanisms underlying the efficacy of a humanized MAb against HER-2/neu in advanced breast cancer.
Main Methods:
- Development and testing of monoclonal antibodies against tumor cell lines.
- Clinical evaluation of a humanized MAb targeting HER-2/neu.
- Preclinical assessment of the MAb's mechanism of action.
Main Results:
- Clinical efficacy of a humanized MAb targeting HER-2/neu has been demonstrated in advanced breast cancer patients.
- Preclinical data suggest the MAb's activity may stem from modulating HER-2/neu receptor properties.
Conclusions:
- Humanized MAbs targeting specific receptors like HER-2/neu show promise in cancer therapy.
- The therapeutic mechanism may involve direct receptor modulation, bypassing traditional immune-mediated tumor cell destruction.
